Evidence map›Paper›PMID 38624434›Full record

ArticleTransactions of the Indian National Academy of Engineering : an international journal of engineering and technology2020

Prototype of a Smart Microfluidic Platform for the Evaluation of SARS-Cov-2 Pathogenesis, Along with Estimation of the Effectiveness of Potential Drug Candidates and Antigen-Antibody Interactions in Convalescent Plasma Therapy.

Nimisha Roy, Jyoti Kashyap, Deepti Verma, Rakesh K Tyagi, Amit Prabhakar

Abstract read
In one paragraph

Article in Transactions of the Indian National Academy of Engineering : an international journal of engineering and technology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. PREFACE on the Special Issue 'Technologies for Fighting COVID-19'.Transactions of the Indian National Academy of Engineering : an international journal of engineering and technology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nimisha RoyDepartment of Applied Science, Indian Institute of Information Technology Allahabad, Deoghat, Jhalwa, Allahabad, 211012 India.
Jyoti KashyapSpecial Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, 110067 India.
Deepti VermaDepartment of Chemistry, University of Allahabad, Prayagraj, India.
Rakesh K TyagiSpecial Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, 110067 India.
Amit PrabhakarDepartment of Applied Science, Indian Institute of Information Technology Allahabad, Deoghat, Jhalwa, Allahabad, 211012 India.ORCID 0000-0002-4631-2734

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Originating in China during December 2019, the novel corona-virus, SARS-CoV-2, has created mayhem worldwide in a very short time. The outbreak has been so rapid and widespread that the only option to treat the patients was administering drugs already available in the market like chloroquine/hydroxychloroquine (an antimalarial drug) and remedesivir. A large number of patients have been cured but the attribution to survival by these drugs has been controversial. Till date, we do not have any specific drug or vaccine available for COVID-19 and the pandemic seems to be far from over. To handle the current challenges posed by the outbreak effectively, we need to employ innovative interdisciplinary approaches. Organ-on-chip (OOC), particularly lung-on-chip, is one such approach which combines the potential of microfluidics, cell culture and molecular biology into a single miniaturised platform. The device is realized to be capable of simulating in-vivo physiological responses of an organ. In the current study, an OOC, which is a multichannel 3D cell culture microfluidic device, is made via soft lithography technique, using polydimethylsiloxane-polymer and diverse polymeric porous/semipermeable membranes. Several polymer membranes i.e. PDMS, polyvinylidene fluoride (PVDF), nitrocellulose, polyester etc., integrated into the microdevices, were efficiently explored to realize their better cell-adhesion and viability property. We also propose for the application of a simple, smart and cost-effective lung-on-chip platform to study the SARS-CoV-2 pathogenesis in humans, drug toxicity testing and provide insights into antigen-antibody interactions. This platform will enable us to study multiple phenomena at a micro-level generating more reliable data and a better understanding of the underlying mechanisms of SARS-CoV-2 infection and pathogenesis.

Indexed as

3D-cell culture platformCell-adhesionCOVID-19Lung-on-chipMicrofluidicsOrgan-on-chipPolymeric-semipermeable-membraneSARS-CoV-2

Identifiers

PMID38624434
PMCPMC7340772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.